Osteoporosis Drugs Market 2025

Osteoporosis Drugs Market Definition

Osteoporosis drugs are medications designed to prevent, treat, or manage osteoporosis—a condition characterized by decreased bone density and increased susceptibility to fractures. The primary goal of these medications is to strengthen bones, reduce bone loss and lower the risk of fractures. The osteoporosis drugs market consists of sales, by entities (organizations, sole traders, or partnerships), of osteoporosis drugs that are primarily used by individuals diagnosed with osteoporosis, including postmenopausal women, older adults and patients undergoing treatments that affect bone density, such as long-term corticosteroid therapy.

Osteoporosis Drugs Market Size

The global osteoporosis drugs market reached a value of nearly $12,885.89 million in 2024, having grown at a compound annual growth rate (CAGR) of 2.42% since 2019. The market is expected to grow from $12,885.89 million in 2024 to $15,695.68 million in 2029 at a rate of 4.02%. The market is then expected to grow at a CAGR of 4.77% from 2029 and reach $19,809.27 million in 2034. Growth in the historic period resulted from the health insurance expansion, increase in bone fractures and comorbidities and government and health initiatives. Factors that negatively affected growth in the historic period were safety concerns. Going forward, increasing aging population, rising healthcare expenditure, economic growth in emerging markets and rising prevalence of osteoporosis will drive the growth. Factor that could hinder the growth of the osteoporosis market in the future include high costs.

Osteoporosis Drugs Market Drivers

The key drivers of the osteoporosis drugs market include: Rising Healthcare Expenditure During the forecast period, the rising healthcare expenditure are expected to propel the growth of the osteoporosis drugs market. Increased healthcare spending enhances R&D efforts for osteoporosis treatments, enabling pharmaceutical companies to develop more effective and innovative drugs. Increased healthcare spending enhances access to medical services, diagnostic tools and treatments, driving earlier diagnoses and improved management of osteoporosis. This boost in patient care raises demand for osteoporosis medications. For instance, according to the economic forecast from the Office for Budget Responsibility (OBR) and Treasury, planned health spending in the UK is expected to rise to £192 billion ($244.43 billion) in 2024/25 from £182 billion ($231.70 billion) in 2022/23. Additionally, according to National Health Expenditures Accounts (NHEA) by KFF, a US-based independent source for health policy research, polling and journalism, health spending in the USA is expected to rise by 5% from 2023 to 2024, reaching $4.9 trillion. Therefore, the rising healthcare expenditure will drive the growth of the osteoporosis drugs market.

Osteoporosis Drugs Market Restraints

The key restraints on the osteoporosis drugs market include: High Cost Of Treatment The high cost of treatment is expected to hinder the osteoporosis drugs market during the forecast period. Osteoporosis medications, particularly newer and more effective options, are often expensive, posing access challenges for patients, especially in regions with limited insurance coverage. Healthcare systems and insurers evaluate cost-effectiveness, potentially limiting reimbursement or increasing co-pays if drug costs outweigh perceived health benefits. This can discourage both patient uptake and provider adoption. For example, according to the National Center for Biotechnology Information, a US-based company advances science and health by providing access to biomedical and genomic information, each year in USA, osteoporosis-related bone fractures cost patients, their families and healthcare system approximately USD 19 billion. Experts estimate that by 2025, osteoporosis will be responsible for three million fractures, costing USD 25.3 billion. Therefore, the high cost of treatment will restrain the growth of the osteoporosis drugs market.

Osteoporosis Drugs Market Trends

Major trends shaping the osteoporosis drugs market include: Innovative Osteoporosis Treatment Launched To Enhance Patient Outcomes Major companies operating in the osteoporosis drugs market are focusing on developing innovative solutions, such as teriparatide Injection for the treatment of treatment osteoporosis to enhance treatment outcomes. Teriparatide is a synthetic form of parathyroid hormone that stimulates bone growth, making it particularly effective for patients with severe osteoporosis or those at high risk of fractures. In November 2023, Apotex Corp, a Canada-based pharmaceutical corporation, launched Teriparatide Injection in the United States, a new treatment for osteoporosis available in a single-patient-use pre-filled pen containing 250 mcg/mL of teriparatide, allowing for 28 daily doses of 20 mcg. This launch addresses the needs of the approximately 10 million Americans affected by osteoporosis, providing an affordable option in the market. Developed in collaboration with Ambio, Inc., the product received FDA approval and reflects Apotex's commitment to enhancing patient access to essential medications. Innovative Approaches And Regulatory Approvals Driving Treatment Advancements Companies in the osteoporosis drugs market are prioritizing the development of innovative solutions, such as obtaining regulatory approvals to enhance treatment outcomes. Regulatory approvals refer to official authorization from health agencies, ensuring new treatments meet safety, efficacy and quality standards before market release. For instance, in November 2024, Teva Pharmaceuticals Inc., a US-based pharmaceutical company received U.S. Food and Drug Administration (FDA) approval for generic version of Forteo (teriparatide injection). This generic medication is recommended for postmenopausal women with osteoporosis at high fracture risk who are unable to use alternative treatments. It is also suitable for men with primary or hypogonadal osteoporosis under similar conditions. Additionally, it applies to both men and women experiencing osteoporosis due to long-term glucocorticoid use, again at high fracture risk and unable to use alternative therapies.

Opportunities And Recommendations In The Osteoporosis Drugs Market

Opportunities – The top opportunities in the osteoporosis drugs markets segmented by type will arise in the bisphosphonates segment, which will gain $1,074.11 million of global annual sales by 2029. The top opportunities in the osteoporosis drugs market segmented by administration will arise in the oral segment, which will gain $1,398.61 million of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by distribution channel will arise in the retail pharmacies segment, which will gain $1,126.32 million of global annual sales by 2029. The top opportunities in the osteoporosis drugs markets segmented by application will arise in the primary osteoporosis segment, which will gain $2,246.06 million of global annual sales by 2029. The osteoporosis drugs market size will gain the most in USA at $870.53 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the osteoporosis drugs companies to focus on developing innovative and accessible treatment solutions, focus on regulatory approvals and innovative treatments, focus on enhancing medication adherence and targeted therapeutic options, focus on RANK ligand inhibitors for business growth, focus on the injectable segment for growth, expand in emerging markets, focus on expanding distribution channels for osteoporosis drugs, focus on developing competitive and flexible pricing strategies for osteoporosis drugs, focus on targeted marketing and educational campaigns for osteoporosis drugs, focus on physician engagement and influencer collaborations for osteoporosis drugs, focus on online sales for growth in osteoporosis drugs market and focus on primary osteoporosis market segment.